Navigation Links
Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:3/16/2009

ASHBURN, Va., March 16 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

The trial is being conducted at approximately 50 hospital sites across the U.S. and has enrolled 1,500 diabetic and/or obese (BMI>30) patients undergoing cardiac surgery. Such patients are generally recognized to be at higher risk of developing sternal wound infections (SWI); a serious and potentially life-threatening complication of cardiac surgery. Patients in the treatment group have two Gentamicin Implants (260 mg total dose) placed between the sternal halves before chest closure and the primary endpoint is total incidence of SWI after 3 months post-surgery. The trial design was based on a published 2,000 patient clinical trial performed in Sweden which demonstrated that the implant significantly reduced the incidence of sternal wound infection (SWI) by 53 percent, increasing to 68 percent reduction in the higher risk patient population. A health economic analysis of the Swedish study has also been published and concluded that routine prophylactic use of the Gentamicin Implant resulted in a net cost saving per patient.

Patient enrolment in a second phase 3 trial being conducted in patients undergoing open colorectal surgery is expected to close later this month. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Coordinating Center for both phase 3 trials.

Dr. Michael Myers, Innocoll's President and CEO commented, "We are delighted to have completed patient enrolment in this phase 3 cardiac surgery trial, which we are running in parallel with the second phase 3 trial in colorectal s
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
9. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
11. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... DUBLIN , May 22, 2015 Research ... announced the addition of the "Latest Regulations ... report to their offering. This ... officially issued a guidance on international multi-center clinical ... , which has begun to be implemented on ...
(Date:5/22/2015)... -- Richmond Pharmacology is a university ... worldwide reputation for excellence in clinical trials. It ... reviewed medical journals. Its officers are engaged with ... about rules for transparency and publication of clinical ... Clinical research is conducted worldwide, therefore ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... Md. , May 26 The U.S. Food and Drug Administration ... liver injury in patients taking the weight-loss medication orlistat, marketed as Xenical and ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ... The FDA has approved a ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it will present at ... on June 9, 2010 , in New York, NY . ... provide an update on the Company,s marketed products and clinical programs. , ... The presentation will be webcast. To access ...
Cached Medicine Technology:FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 2FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 3ISTA Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:5/22/2015)... VIEW, California (PRWEB) May 22, 2015 Coco ... has set a RecordSetter.com World Record at the 104th running ... Libre coconut water ice luge served 315 people in one ... Bay to Breakers race is so true to the heart ... we felt bringing an ice luge to the finish line ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all ... company specialize in include decks, additions, kitchen remodeling, interior ... much more. , The redesigned logo is a ... company. It includes two geometrical lines that represent the ... to be used with many things associated with the ...
(Date:5/22/2015)... 22, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing , is proud ... respected All American National athlete, to the Wimbledon Athletics ... the high level of testing and information it provides ... their athletic trainers, this way they can focus on ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... of Multifamily Housing, Marc Zuluaga, has been selected by ... innovative engineering. The award winners are featured in the ... given to 40 building industry professionals age 40 and ... to the building community, as well as in other ...
(Date:5/22/2015)... 2015 Bryce Henson, local fitness icon ... Boot Camp, recently accepted his program’s 100th client. Henson ... launch of his location evidences the powerful impact his ... Fit Body Boot Camp is the nation’s most popular ... hundreds of locations across North America, Europe and Australia. ...
Breaking Medicine News(10 mins):Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2
... Preclinical Data Indicate New HspE7 Promotes More ... Nov. 5 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) ... at the 24th International Papillomavirus,conference, the largest ... in the field of human papillomavirus (HPV), ...
... Corp. (OTC Bulletin,Board: CRDT), a leading healthcare staffing ... to Vice President of Operations of Crdentia,s,newly acquired ... Mr. Jones joins Crdentia from ATS Health ... health staffing services with six offices in,Florida, one ...
... care insurance provides important financial protection and peace ... of mind for ... Treaty American,Corporation, a pioneer in the long-term care insurance (LTCi) ... awareness of,long-term care options during the month of November. ...
... Nov. 5 ,Following consultation with the German Federal ... Food and Drug Administration (FDA),Health Canada, and other ... to temporarily suspend worldwide marketing of Trasylol(R),(aprotinin injection) ... can,be compiled, received and evaluated. The company took ...
... young inner-city children appears to be more unpredictable than ever, ... wise move as a hedge against dangerous flare-ups of wheezing ... from the Johns Hopkins Childrens Center. Current asthma guidelines call ... six months may be too long for many patients, researchers ...
... better when the dark delight is consumed, study suggests , ... A Japanese study finds that flavonoid-rich dark chocolate can improve ... as coronary flow velocity reserve (CFVR), an indicator of the ... blood flow in response to medications. , The two-week trial ...
Cached Medicine News:Health News:Nventa presents HspE7 data at international HPV conference 2Health News:Nventa presents HspE7 data at international HPV conference 3Health News:Nventa presents HspE7 data at international HPV conference 4Health News:Nventa presents HspE7 data at international HPV conference 5Health News:Crdentia Announces Appointment of Tim Jones to Senior Management Team 2Health News:Crdentia Announces Appointment of Tim Jones to Senior Management Team 3Health News:Penn Treaty Urges Americans To Plan for Their Future During Long-Term Care Awareness Week 2Health News:Penn Treaty Urges Americans To Plan for Their Future During Long-Term Care Awareness Week 3Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 2Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 3Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 4Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Chocolate Has Sweet Effect on Blood Flow 2
... Post Operative Pin® Knee Brace (DxHDDLP) has a ... drop lock lever and laminate liner. The precision ... brace from migrating on the leg during ambulation. ... that controls flexion and extension in 5° increments ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
... The Drytex Adjustable Patella Donut ... a unique nylon core and polyester ... airflow. A trimable full-circumference donut provides ... who have neoprene based allergies or ...
... for total knees, meniscus repairs, regenerative chondroplasty, ... TROM gives easy-to-use range of motion control ... Rehab TROM can be used as a ... purchased separately be used with the TROM ...
Medicine Products: